George A Saviolakis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
George A Saviolakis has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bryan Smith
United States Army Medical Materiel Development Activity, 1430 Veterans Drive, Fort Detrick, Maryland 21702, USA
1 shared publication - Kevin J. Leary
US Army Medical Material Development Activity, Ft Detrick, MD, USA
1 shared publication - Louis R. Cantilena
Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD, USA
1 shared publication - Peter J. Weina
Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
1 shared publication - Qigui Li
Department of Drug Discovery, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910 USA
1 shared publication - Robert Scott Miller
US Army Medical Materiel Development Activity, Fort Detrick, Maryland2currently with the Uniformed Services University of the Health Sciences, Bethesda, Maryland
1 shared publication
Latest Publications
- Open Access
- 1 August 2012
- Published by Springer Nature in Malaria Journal
- Vol. 11 (1) , 255
Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study
Severe malaria results in over a million deaths every year, most of them in children aged less than five years and living in sub-Saharan Africa. Injectable artesunate (AS) was recommended as initial treatment for severe malaria by WHO in 2006. The Walter Reed Army Institute of Research (WRAIR) has been developing a novel good manufacturing practice (GMP) injection of AS, which was approved by the US FDA for investigational drug use and distribution by the CDC.
- 1 August 2012
- Published by Springer Nature in Malaria Journal
- Vol. 11 (1) , 255
Open AccessPharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study
Severe malaria results in over a million deaths every year, most of them in children aged less than five years and living in sub-Saharan Africa. Injectable artesunate (AS) was recommended as initial treatment for severe malaria by WHO in 2006. The Walter Reed Army Institute of Research (WRAIR) has been developing a novel good manufacturing practice (GMP) injection of AS, which was approved by the US FDA for investigational drug use and distribution by the CDC.